Epidemiology of psoriasis in Italy: burden, cost, comorbidities and patients’ satisfaction. A systematic review

Main Article Content

Vincenza Gianfredi https://orcid.org/0000-0003-3848-981X
Giulia Casu
Lucia Bricchi
Erika Kacerik
Franco Rongioletti
Carlo Signorelli

Keywords

systematic review, psoriasis, epidemiology, comorbidity, costs, italy

Abstract

Background and aim: The Italian data on psoriasis are partial and, in most cases, come from monocentric studies, not representative of the population. Our aim was to conduct a systematic review of the available evidence in order to get the overall picture of the Italian epidemiology (prevalence and incidence); burden of disease (direct and indirect costs, the impact on quality of life); comorbidities; and finally, the patients’ satisfaction and acknowledgement of both the disease and the care services available. Methods: This systematic review followed the guidelines of the Cochrane Collaboration and the Prepared Items for Systematic Reviews and Meta-Analysis (PRISMA) 2020. The literature search was conducted on PubMed/Medline and Scopus.


Results: Out of 387 retrieved articles, 41 were included in the analysis. Psoriasis is a frequent condition in Italy: the prevalence is between 1,8% and 4,8% and the incidence is between 107,742 and 230,62 per 100.000 person-years. The most frequent comorbidities associated to psoriasis are: diabetes, hypertension, obesity, depression, cardiovascular diseases, hypertriglyceridemia, and hypercholesterolemia. The quality of life and severity of the disease are mostly affected by other concurrent diseases, early onset of the disease, low income, and low level of education.


The costs of psoriasis were estimated between 500 euro and 15.000 euro depending on the disease’s severity, the treatments used and hospitalization. Conclusions: In conclusion, psoriasis is a high-impact chronic disease. It is therefore fundamental to advocate a multidisciplinary approach to obtain a better health outcome, the patients’ management and the cost savings could benefit from it.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...
Abstract 876 | PDF Downloads 492

References

1. Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol 2011; 65 (4):870-3.
2. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162 (3):633-6.
3. Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci 2019; 20 (18).
4. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol 2012; 175 (5):402-13.
5. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2:e54.
6. Tobin AM, Hackett CB, Rogers S, et al. Body mass index, waist circumference and HOMA-IR correlate with the Psoriasis Area and Severity Index in patients with psoriasis receiving phototherapy. Br J Dermatol 2014; 171 (2):436-8.
7. Kumar S, Han J, Li T, Qureshi AA. Obesity, waist circumference, weight change and the risk of psoriasis in US women. J Eur Acad Dermatol Venereol 2013; 27 (10):1293-8.
8. Rousset L, Halioua B. Stress and psoriasis. Int J Dermatol 2018; 57 (10):1165-72.
9. Nograles KE, Brasington RD, Bowcock AM. New insights into the pathogenesis and genetics of psoriatic arthritis. Nat Clin Pract Rheumatol 2009; 5 (2):83-91.
10. Shao CG, Zhang GW, Wang GC. Distribution of psoriasis in China: a nationwide screening. Proc Chin Acad Med Sci Peking Union Med Coll 1987; 2 (2):59-65.
11. Yang YC, Cheng YW, Lai CS, Chen W. Prevalence of childhood acne, ephelides, warts, atopic dermatitis, psoriasis, alopecia areata and keloid in Kaohsiung County, Taiwan: a community-based clinical survey. J Eur Acad Dermatol Venereol 2007; 21 (5):643-9.
12. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 2017; 31 (2):205-12.
13. Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond) 2017; 17 (1):65-70.
14. World Health Organization. Global report on psoriasis. 2016.
15. Gisondi P, Geat D, Pizzolato M, Girolomoni G. State of the art and pharmacological pipeline of biologics for chronic plaque psoriasis. Curr Opin Pharmacol 2019; 46:90-9.
16. Burgos-Pol R, Martinez-Sesmero JM, Ventura-Cerda JM, Elias I, Caloto MT, Casado MA. The Cost of Psoriasis and Psoriatic Arthritis in 5 European Countries: A Systematic Review. Actas Dermosifiliogr 2016; 107 (7):577-90.
17. Colombo GL, Di Matteo S, Peris K, et al. A cost-utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. Clinicoecon Outcomes Res 2009; 1:53-9.
18. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (7):e1000097.
19. Assessing work-related productivity loss and indirect costs of psoriasis across six countries. The British journal of dermatology 2020; 183 (3):e65-e90.
20. Bewley A, Burrage DM, Ersser SJ, Hansen M, Ward C. Identifying individual psychosocial and adherence support needs in patients with psoriasis: a multinational two-stage qualitative and quantitative study. Journal of the European Academy of Dermatology and Venereology : JEADV 2014; 28 (6):763-70.
21. Gottlieb A, Gratacos J, Dikranian A, et al. Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe. Rheumatology international 2019; 39 (1):121-30.
22. Narayanan S, Guyatt V, Franceschetti A, Hautamaki EL. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckland, NZ) 2015; 5:1-7.
23. Rodríguez-Zúñiga MJM, García-Perdomo HA. Systematic review and meta-analysis of the association between psoriasis and metabolic syndrome. Journal of the American Academy of Dermatology 2017; 77 (4):657-66.e8.
24. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155 (4):729-36.
25. Griffiths CEM, Augustin M, Naldi L, et al. Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. J Eur Acad Dermatol Venereol 2018; 32 (9):1523-9.
26. Mantovani L, Medaglia M, Piacentini P, et al. Burden of Moderate-to-Severe Plaque Psoriasis and New Therapeutic Approaches (Secukinumab): An Italian Perspective. Dermatol Ther (Heidelb) 2016; 6 (2):151-67.
27. Dini V, Martini P, Bellini M, Bagnoni G, Marsili F, Lancia U. Psoriatic arthritis prevalence in the clinical practice of dermatologists in North-West Tuscany centers of excellence: a screening experience. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2017; 152 (1):24-7.
28. Gisondi P, Farina S, Giordano MV, Zanoni M, Girolomoni G. Attitude to treatment of patients with psoriasis attending spa center. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2012; 147 (5):483-9.
29. Migkos MP, Somarakis GP, Markatseli TE, Voulgari PV, Drosos AA. Epidemiological characteristics of psoriatic arthritis. Clinical and experimental rheumatology 2019; 37 (2):324-32.
30. Neri L, Miracapillo A. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists' preferences for alternative treatment options. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2015; 150 (1):19-26.
31. Sategna-Guidetti C, Bracco E, Marucco E, Bianco L. Psoriasis and Crohn's disease in Italy. Digestive diseases and sciences 1988; 33 (11):1496.
32. Valent F, Tullio A, Errichetti E, Stinco G. The epidemiology of psoriasis in an Italian area: population-based analysis of administrative data. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020; 155 (5):652-7.
33. Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. European journal of dermatology : EJD 2010; 20 (5):593-8.
34. Villani A, Cinelli E, Fabbrocini G, Megna M. Psoriasis awareness among general population: preliminary results of an online survey. Italian journal of dermatology and venereology 2021.
35. Giacomelli R, Gorla R, Trotta F, et al. Quality of life and unmet needs in patients with inflammatory arthropathies: results from the multicentre, observational RAPSODIA study. Rheumatology (Oxford, England) 2015; 54 (5):792-7.
36. Sampogna F, Gisondi P, Melchi CF, et al. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151 (3):594-9.
37. Biondi Oriente C, Scarpa R, Oriente P. Prevalence and clinical features of juvenile psoriatic arthritis in 425 psoriatic patients. Acta Derm Venereol Suppl (Stockh) 1994; 186:109-10.
38. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70 (5):871-81 e1-30.
39. Balato A, Caiazzo G, Balato N, Napolitano M, group Ls. Psoriatic arthritis onset in psoriatic patients receiving UV phototherapy in Italy. G Ital Dermatol Venereol 2020; 155 (6):733-8.
40. Morici N, Ferri LA, Alicandro G, et al. Psoriasis and the risk of acute coronary syndrome in the elderly. Int J Cardiol 2018; 273:44-6.
41. Altobelli E, Maccarone M, Petrocelli R, et al. Analysis of health care and actual needs of patients with psoriasis: a survey on the Italian population. BMC public health 2007; 7:59.
42. Augustin M, Vietri J, Tian H, Gilloteau I. Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries. Journal of the European Academy of Dermatology and Venereology : JEADV 2017; 31 (8):1316-23.
43. Bardazzi F, Amerio P, Amoruso G, et al. Investigating psoriasis awareness among patients in Italy: validation of a questionnaire. Eur Rev Med Pharmacol Sci 2014; 18 (22):3435-52.
44. Bardazzi F, Amerio P, Amoruso G, et al. Psoriasis awareness among Italian patients: results of a nationwide survey. G Ital Dermatol Venereol 2016; 151 (1):1-8.
45. Bardazzi F, Tengattini V, Rucci P, et al. Socio-economic status and severity of plaque psoriasis: a cross-sectional study in the metropolitan city of Bologna. Eur J Dermatol 2019; 29 (2):197-202.
46. Biondi Oriente C, Scarpa R, Pucino A, Oriente P. Psoriasis and psoriatic arthritis. Dermatological and rheumatological co-operative clinical report. Acta Derm Venereol Suppl (Stockh) 1989; 146:69-71.
47. Caldarola G, De Simone C, Talamonti M, et al. Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. Eur J Dermatol 2019; 29 (2):192-6.
48. Carpentieri A, Pacello L, De Marco IM, Loiacono A, Picconi O, Loconsole F. Retrospective analysis of the effectiveness and costs of traditional treatments for moderate-to-severe psoriasis: A single-center, Italian study. J Dermatolog Treat 2016; 27 (5):399-405.
49. Cimmino MA. Epidemiology of psoriasis and psoriatic arthritis. Reumatismo 2007; 59 Suppl 1:19-24.
50. Colombo G, Altomare G, Peris K, et al. Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 2008; 4 (2):559-68.
51. Conforti C, Currado D, Navarini L, et al. Moderate-to-severe plaque psoriasis, described by PASI >/=10%, can be associated with higher cardiovascular risk according to seven risk algorithms: Results of a 10-year single-center retrospective study and clinical management of psoriatic patients with cardiovascular risk. Dermatol Ther 2020; 33 (6):e14451.
52. Conti A, Giovannini L, Mandel VD, et al. Chronic kidney disease in psoriasis: a cohort study. J Dtsch Dermatol Ges 2020; 18 (5):438-45.
53. De Socio A, Perrotta FM, Grasso GM, Lubrano E. Incidence of rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica in an inland area of central Italy: results of the CAMPO-RHE study. Postgraduate medicine 2018; 130 (1):137-41.
54. Esposito M, Faleri S, Babino G, et al. From patients' needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI' experience. J Int Med Res 2016; 44 (1 suppl):95-9.
55. Esposito M, Saraceno R, Giunta A, Maccarone M, Chimenti S. An Italian study on psoriasis and depression. Dermatology (Basel, Switzerland) 2006; 212 (2):123-7.
56. Degli Esposti L, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics 2018; 12:151-8.
57. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res 2014; 14 (5):685-705.
58. Finzi A, Colombo D, Caputo A, et al. Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. J Eur Acad Dermatol Venereol 2007; 21 (9):1161-9.
59. Finzi AF, Benelli C. A clinical survey of psoriasis in Italy: 1st AISP report. Interdisciplinary Association for the Study of Psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 1998; 10 (2):125-9.
60. Finzi AF, Mantovani LG, Belisari A, Italian Association for Studies on P. The cost of hospital-related care of patients with psoriasis in Italy based on the AISP study. Associazione Italiana Studi Psoriasi. Journal of the European Academy of Dermatology and Venereology : JEADV 2001; 15 (4):320-4.
61. Gisondi P. Hyperuricemia in patients with chronic plaque psoriasis. Drug Dev Res 2014; 75 Suppl 1:S70-2.
62. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 2016; 30 (2):282-7.
63. Gisondi P, Fantin F, Del Giglio M, et al. Chronic plaque psoriasis is associated with increased arterial stiffness. Dermatology (Basel, Switzerland) 2009; 218 (2):110-3.
64. Gisondi P, Farina S, Giordano MV, Girolomoni G. Usefulness of the framingham risk score in patients with chronic psoriasis. Am J Cardiol 2010; 106 (12):1754-7.
65. Gisondi P, Girolomoni G. Patients' perspectives in the management of psoriasis: the Italian results of the Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey. J Dermatolog Treat 2017; 28 (5):390-3.
66. Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51 (4):758-64.
67. Luca M, Musumeci ML, Bardazzi F, et al. Biologic agents perception in patients attending for the first-time to psoriasis centers: a multicenter Italian survey. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 2020; 155 (2):150-4.
68. Parisi R, Symmons DP, Griffiths CE, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133 (2):377-85.
69. Parodi A, Aste N, Calvieri C, et al. Metabolic syndrome prevalence in psoriasis: a cross-sectional study in the Italian population. American journal of clinical dermatology 2014; 15 (4):371-7.
70. Pezzolo E, Ciampichini R, Cazzaniga S, Sampietro G, Zucchi A, Naldi L. Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy. Archives for dermatological research = Archiv fur dermatologische Forschung 2021; 313 (4):255-61.
71. Prignano F, Rogai V, Cavallucci E, Bitossi A, Hammen V, Cantini F. Epidemiology of Psoriasis and Psoriatic Arthritis in Italy-a Systematic Review. Current rheumatology reports 2018; 20 (7):43.
72. Proietti I, Raimondi G, Skroza N, et al. Cardiovascular risk in psoriatic patients detected by heart rate variability (HRV) analysis. Drug Dev Res 2014; 75 Suppl 1:S81-4.
73. Renzi C, Di Pietro C, Gisondi P, et al. Insufficient knowledge among psoriasis patients can represent a barrier to participation in decision-making. Acta dermato-venereologica 2006; 86 (6):528-34.
74. Ricci F, Panebianco A, Fania L, et al. Age-specific prevalence of psoriasis in an unselected sample of 25,956 Italian hospital inpatients: evidence for selective excess mortality after 70 years of age. Eur J Dermatol 2018; 28 (1):103-5.
75. Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. Journal of the European Academy of Dermatology and Venereology : JEADV 2008; 22 (3):324-9.
76. Sardu C, Cocco E, Mereu A, et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PloS one 2012; 7 (3):e32487.
77. Scarpa R, Oriente P, Pucino A, et al. Psoriatic arthritis in psoriatic patients. Br J Rheumatol 1984; 23 (4):246-50.
78. Spandonaro F, Ayala F, Berardesca E, et al. The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2014; 28 (3):285-95.
79. Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work-related productivity loss and indirect costs from a survey of patients with psoriasis. The British journal of dermatology 2020; 183 (3):548-58.
80. Caldarola G, De Simone C, Talamonti M, et al. Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. Eur J Dermatol 2019; 29 (2):192-6.
81. Danielsen K, Duvetorp A, Iversen L, et al. Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Acta Derm Venereol 2019; 99 (1):18-25.
82. Zheng X, Wang Q, Luo Y, et al. Seasonal Variation of Psoriasis and Its Impact in the Therapeutic Management: A Retrospective Study on Chinese Patients. Clin Cosmet Investig Dermatol 2021; 14:459-65.
83. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4:35.
84. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002; 47 (4):512-8.
85. Christophers E, Barker JN, Griffiths CE, et al. The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. Journal of the European Academy of Dermatology and Venereology : JEADV 2010; 24 (5):548-54.
86. Mahler R, Jackson C, Ijacu H. The burden of psoriasis and barriers to satisfactory care: results from a Canadian patient survey. J Cutan Med Surg 2009; 13 (6):283-93.
87. Poulin Y, Papp KA, Wasel NR, et al. A Canadian online survey to evaluate awareness and treatment satisfaction in individuals with moderate to severe plaque psoriasis. Int J Dermatol 2010; 49 (12):1368-75.
88. Ismail D, McAteer H, Majeed-Ariss R, McPhee M, Griffiths CEM, Young HS. Research priorities and identification of a health-service delivery model for psoriasis from the UK Psoriasis Priority Setting Partnership. Clin Exp Dermatol 2021; 46 (2):276-85.
89. Qureshi AA, Husni ME, Mody E. Psoriatic arthritis and psoriasis: need for a multidisciplinary approach. Semin Cutan Med Surg 2005; 24 (1):46-51.
90. Gianfredi V, Odone A, Fiacchini D, Rosselu R, Battista T, Signorelli C. Trust and reputation management, branding, social media management nelle organizzazioni sanitarie: Sfide e opportunity per la comunita igienistica italiana. Journal of Preventive Medicine and Hygiene 2019; 60 (3):E108-E9.
91. Mahroum N, Bragazzi NL, Sharif K, et al. Leveraging Google Trends, Twitter, and Wikipedia to Investigate the Impact of a Celebrity's Death From Rheumatoid Arthritis. J Clin Rheumatol 2018; 24 (4):188-92.
92. Gianfredi V, Provenzano S, Santangelo OE. What can internet users' behaviours reveal about the mental health impacts of the COVID-19 pandemic? A systematic review. Public Health 2021; 198:44-52.
93. Gianfredi V, Nucci D, Balzarini M, et al. E-Coaching: the DianaWeb study to prevent breast cancer recurrences. Clin Ter 2020; 170 (1):e59-e65.
94. Gianfredi V, Balzarini F, Gola M, et al. Leadership in Public Health: Opportunities for Young Generations Within Scientific Associations and the Experience of the "Academy of Young Leaders". Front Public Health 2019; 7:378.
95. Signorelli C, Fara GM. COVID-19: Hygiene and Public Health to the front. Acta Biomed 2020; 91 (3-S):7-8.


Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 > >> 

Similar Articles

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 > >> 

You may also start an advanced similarity search for this article.